Information  X 
Enter a valid email address

BioPharma Credit PLC (BPCR)

  Print   

Thursday 24 June, 2021

BioPharma Credit PLC

Result of GM and AGM

RNS Number : 0387D
BioPharma Credit PLC
24 June 2021
 

BIOPHARMA CREDIT PLC

 

(THE "COMPANY")

 

 

RESULT OF GM AND AGM

 

 

General Meeting

 

The Company is pleased to announce that, at the General Meeting held today, both resolutions were put to the meeting and passed on a show of hands.

 

The proxy votes received in relation to this resolution was as follows:

 

Resolutions

Votes

For

%

Votes Against

%

Votes at Chairman's Discretion

Votes Withheld

1: To appoint PricewaterhouseCoopers LLP as auditor to the Company

603,573,041

98.37

10,013,980

1.63

0

0

2: To authorise the Directors to determine the remuneration of PricewaterhouseCoopers LLP as the auditor

613,573,041

99.99

13,980

0.01

0

0

 

 

 

Annual General Meeting

 

The Company is pleased to announce that, at the Annual General Meeting that was adjourned on 17 June 2021 and reconvened today, Resolution 1 was put to the meeting and passed on a show of hands.

 

The proxy votes received in relation to this resolution was as follows:

 

Resolutions

Votes

For

%

Votes Against

%

Votes at Chairman's Discretion

Votes Withheld

1: To receive and accept the annual report and financial statements

644,324,577

100

0

0

0

0

 

24 June 2021

 

 

Enquiries

 

BioPharma Credit plc

 

via Link Company Matters Limited

 

Company Secretary

 

+44 (0)1392 477 500

 

 

 

Buchanan

 

+44 (0)20 7466 5000 / [email protected]

 

David Rydell

 

Mark Court

 

Jamie Hooper

 

Henry Wilson

 

 

 

Notes to Editors:

 

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

 

 

 

LEI: 213800AV55PYXAS7SY24

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGFIMTTMTBTBRB

a d v e r t i s e m e n t